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the following website: http://aidsinfo.nih.gov/Guidelines/Default.aspx 
Guidance for Non-HIV-Specialized Providers Caring for 
HIV-Infected Residents Displaced from Disaster Areas 
 
 
The following information provides guidance to health care providers attending to the medical needs of 
HIV-infected adults (including pregnant women) or children displaced from disaster areas who have not 
yet secured HIV care in the areas where they have relocated. 
 
Management of antiretroviral therapy is complex and, if possible, should be done with the assistance of 
clinicians with experience in HIV care. Medical consultation may also be available at specific local or 
regional HIV clinics. After the initial assessment of a patient’s immediate medical needs, if at all possible, 
the patient should be referred to the care of an HIV clinician in the area. 
 
INITIAL ASSESSMENT 
 
1. Assess the patient’s general health and need for immediate medical intervention. Acute 
illnesses should be diagnosed and attended to promptly. 
 
2. Obtain the following information from the patient: 
 
a. Name, location, phone number, pager number, and e-mail address of the primary HIV 
care provider/clinic and research staff (if the patient is participating in a research study 
such as a clinical trial). 
 
b. The name, location, and phone number of the pharmacy where the patient obtained 
medications. 
 
c. Pertinent past medical history (including history of opportunistic infections [OIs] or 
malignancies and other medical conditions such as hypertension, diabetes mellitus). 
 
d. Latest known CD4 cell count/percentage and viral load and approximate date when they 
were obtained. 
 
e. Current medications including: 
i. antiretroviral drugs* (most recent/current drugs and drugs used in the past, if 
available) 
ii. Any investigational medication (if the patient is participating in a clinical trial, 
obtain information about the clinical trial site and contact information, if 
available) 
iii. medications for treatment of OIs 
iv. medications for prevention of OIs 
v. other medications 
* Note: Using pamphlets or booklets with images of antiretroviral drugs and other medications may help patients to recall or 
identify their medications. The images of Food and Drug Administration (FDA)-approved antiretroviral medications can be 
found at http://aidsinfo.nih.gov/contentfiles/HIV_Pill_Poster.pdf 
 
f. Brief family history including any HIV-infected children or other family members. 
 
g. History of drug allergy and type of reactions—especially ask if there is any history of 
serious reactions to antiretroviral medications or drugs used for treatment or prevention 
of OIs, such as trimethoprim-sulfamethoxazole. Patients who have had positive 
genetic tests for the HLA-B*5701 allele should not be given abacavir or fixed-
dose combinations containing abacavir because HLA-B*5701 predisposes 
patients to life-threatening hypersensitivity reactions. 
 
h. History of intolerance to antiretroviral medications and other medications. 
 
i. Vaccination history (may be obtainable from local/regional/state registries). 
 
 
GENERAL MEDICATION MANAGEMENT STRATEGIES  
 
Patients who had their antiretroviral therapy and/or prophylaxis or treatment for OIs interrupted by 
disaster-related displacement should restart these medications as soon as possible. There is no need to 
start antiretroviral therapy immediately in those HIV-infected patients who were not receiving 
antiretroviral medications before the disaster. In these patients, initiation of therapy can be delayed until a 
more thorough assessment can be made; if necessary, patients should be referred to a local HIV specialist 
for further medical care.  
 
 
1. Antiretroviral Therapy Management 
 
a. All antiretroviral drugs should be restarted at the same time. If the patient was receiving 
nevirapine (Viramune) as part of a regimen and has not taken nevirapine for more than 7 
days, it should be restarted with a 2-week “lead-in” period, giving half the daily dose 
once daily for 14 days and then standard twice-daily dosing. 
 
b. In general, the patient should be on a combination regimen consisting of a total of at least 
three different antiretroviral drugs. 
 
c. Note that some antiretroviral drugs are available in fixed-dose formulations where two or 
more drugs are combined into one pill (e.g., Atripla® = efavirenz + emtricitabine + 
tenofovir; Combivir® = zidovudine + lamivudine; Complera® = rilpivirine + tenofovir + 
emtricitabine; Epzicom® = abacavir + lamivudine; and Truvada® = emtricitabine + 
tenofovir). 
 
d. Pediatric patients may be taking liquid formulations, some of which may need to be 
refrigerated. Special attention should be paid to appropriate weight- or surface area-based 
dosing for pediatric patients. 
 
e. If patients cannot recall drug dosages or cannot recall their regimens, consult an HIV care 
specialist or consultation service for recommendations or contact the pharmacy where 
they most recently obtained their medications.  
 
f. Patients with a history of the following serious reactions to the following agents should 
not be rechallenged with the same drugs: 
i. Symptomatic hepatitis or Stevens-Johnson syndrome from nevirapine 
(Viramune® or Viramune XR®) 
ii. Hypersensitivity reaction from abacavir (Epzicom®, Ziagen®, or 
Trizivir®) 
iii. Pancreatitis from didanosine (Videx® or Videx EC®) 
iv. Serious rash with any antiretroviral medication 
 
g. Antiretroviral medications may interact with each other and with many other drugs. 
Please consult product labels, an HIV care specialist, or a pharmacist when concerned 
about drug-drug interactions. Tables with common antiretroviral drug interactions can 
also be found in the latest adult and pediatric antiretroviral guidelines as well as 
guidelines for treatment of pregnant women and prevention of mother-to-child 
transmission of HIV at http://aidsinfo.nih.gov/guidelines. 
 
h. The above guidelines also include information regarding dosing and adverse effects of 
antiretroviral drugs as well as special considerations in certain patient populations, such 
as patients coinfected with hepatitis B, hepatitis C, and tuberculosis. 
 
2. Caring for the HIV-Infected Pregnant Women 
 
a. All HIV-infected pregnant women should be entered into standard prenatal/obstetric care 
as soon as possible. 
 
b. The National Perinatal HIV Hotline service provides clinicians with 24 hour 
consultations with experts on treating HIV-infected pregnant women and HIV-
exposed infants: 888-448-8765. The hotline also serves as a clinicians’ network and can 
assist providers with identifying clinicians nationwide who have experience in the 
management of HIV-infected pregnant women and HIV-exposed infants. 
 
c. HIV-infected pregnant women who discontinued antiretroviral drugs used for treatment 
or prevention of mother-to-child transmission of HIV during displacement should 
urgently restart therapy. 
 
d. Pregnant women in the first trimester should not receive efavirenz (in Sustiva® or 
Atripla®) because of potential teratogenicity. 
 
e. All HIV-infected pregnant women who are in the second or third trimester should be 
receiving antiretroviral therapy regardless of their CD4 count. In general, three 
antiretroviral drugs are used for prevention of mother-to-child transmission. 
 
f. Pregnant women with CD4 counts >250 cells/mm3 should not be started on nevirapine 
(Viramune®) as part of the new regimen because of the risk of serious liver toxicities. 
 
g. Elective cesarean delivery is recommended for HIV-infected pregnant women who have 
HIV RNA >1,000 copies/mL in the late third trimester (i.e., >36 weeks’ gestation), 
regardless of whether they are receiving antiretroviral drugs (see perinatal guidelines, 
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women 
for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the 
United States for dosing, available at: 
http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf). 
 
h. HIV-infected women in labor should receive their typical oral antiretroviral regimen plus 
intravenous zidovudine (abbreviated as AZT or ZDV). (For dosing, see Table 7 in 
perinatal guidelines, available at: http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf.) 
Infants should receive ZDV prophylaxis for 6 weeks (Table 7 of the perinatal guidelines). 
Recommendations on infant prophylaxis for special situations (e.g., when the mother has 
not received any antepartum antiretroviral drugs) where additional infant drugs may be 
administered are available in the perinatal guidelines at 
http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. 
 
i. HIV-infected women in the United States should not breastfeed their infants. 
 
j. Treatment and prophylaxis for OIs should also be restarted. A section on “Special 
Consideration during Pregnancy” is available under each OI in the most current 
guidelines for treatment and prevention of OIs (http://aidsinfo.nih.gov). 
 
k. As soon as possible, HIV-infected pregnant women should be referred to specialists with 
expertise in managing these patients for obstetric as well as HIV management. 
 
For more comprehensive information regarding antiretroviral therapy, please go to 
http://aidsinfo.nih.gov/guidelines/. 
 
 
3. Prophylaxis for Opportunistic Infections 
 
OI prophylaxis that had been interrupted should be continued as soon as possible. For more detailed 
information and recommendations regarding prevention and treatment of OIs in adult and pediatric 
patients, please refer to the guidelines at http://aidsinfo.nih.gov/guidelines/. 
 
Indication OI  Prophylaxis regimen 
Adults, adolescents, and children >6 years of 
age:  Latest known CD4 count <200 cells/mm3 
or CD4 percentage <14% or history of 
Pneumocystis jirovecii pneumonia (PCP) 
 
Children 1–5 years of age: Latest known CD4 
count <500 cells/mm3 or CD4 percentage <15% 
 
Children <12 months of age: 
1.  All infants born to women with HIV 
infection starting at age 4–6 weeks, after 
completion of the zidovudine prophylaxis 
regimen, unless there is adequate test 
information to presumptively exclude HIV 
infection 
2.  All HIV-infected infants <12 months of age. 
 
 
Prophylaxis against 
Pneumocystis jirovecii 
pneumonia (PCP) 
1st Line: 
trimethoprim-sulfamethoxazole 
 
Alternatives: 
dapsone or 
atovaquone or monthly 
inhaled pentamidine  
Adults, adolescents, and children >6 years of 
age:  Latest known CD4 count <50 cells/mm3 
 
Children 1–2 years of age:  Latest known CD4 
count <500 cells/mm3 
 
Prophylaxis against 
disseminated 
Mycobacterium avium 
complex infection 
Azithromycin 
Children <1 year of age:  Latest known CD4 
count <750 cells/mm3 
 
 
4. Vaccinations 
General Recommendations: 
a. Practitioners should refer to the Centers for Disease Control and Prevention (CDC) Web site 
(http://emergency.cdc.gov/disasters/alldisasters.asp_and 
http://emergency.cdc.gov/disasters/disease/facts.asp) for updated general recommendations 
for individuals displaced by disasters. 
b. Inactivated influenza vaccine is recommended for all HIV-infected patients (adult or pediatric 
and including pregnant women). This is especially important as the residents continue to 
reside in large crowded areas. 
c. All patients who received immunization at temporary medical care facilities should be given 
written documentation of the date and types of such immunization as records for their 
primary HIV care providers. If available, immunization administration can be submitted to a 
local/area immunization registry. 
 
 
Specific Recommendations for Adult HIV Patients: 
a. Adult formulation of Tetanus/diphtheria toxoids/acellular pertussis (Tdap) should be 
given to adult (including pregnant women) and adolescent patients with HIV if it has been at 
least 10 years since last vaccination or vaccination date unknown. 
 
Specific Recommendations for Pediatric HIV Patients: 
HIV-infected children should adhere to the routine childhood immunization schedule 
(http://www.cdc.gov/nip/recs/child-schedule.html). (The complete recommendations on immunization for 
HIV-infected children can be found in the Guidelines for Prevention and Treatment of Opportunistic 
Infections in HIV-Exposed and Infected children, available at: http://aidsinfo.nih.gov.) 
 
More information regarding antiretroviral management in adult, pregnant, and pediatric patients as well as 
recommendations for prophylaxis and treatment of specific OIs can be found at 
http://aidsinfo.nih.gov/guidelines/. 
 
 
